Recovery Or Purification Patents (Class 435/239)
-
Patent number: 9023603Abstract: The invention provides compositions and methods useful to prepare segmented, negative strand RNA viruses, e.g., orthomyxoviruses such as influenza A viruses, entirely from cloned cDNAs and in the absence of helper virus.Type: GrantFiled: December 20, 2011Date of Patent: May 5, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann
-
Patent number: 9012198Abstract: The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus. The present invention relates to a purified wild type, attenuated and/or recombinant Orthopoxvirus obtained by the method of the invention and to a pharmaceutical composition, preferably a vaccine, comprising said purified Orthopoxvirus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. The present invention also relates to the use of an immortalized avian cell line obtained from an avian cell belonging to the Anatidae family, in particular Cairina moschata immortalized avian cell lines comprising a nucleic acid sequence coding a telomerase reverse transcriptase (TERT) and optionally an E1A nucleic acid sequence, for the production of a wild type, attenuated and/or recombinant Orthopoxvirus according to the process of the invention.Type: GrantFiled: November 12, 2013Date of Patent: April 21, 2015Assignee: Transgene S.A.Inventors: Claude Sene, Sylvie Campourcy, Yves Cordier
-
Patent number: 9006420Abstract: A simple and convenient method for concentrating a biomolecule, including protein or nucleic acid molecules, from a sample. Purified and isolated biomolecules obtained by this method. Methods for improving the specificity or sensitivity of detecting a biomolecule by concentration and/or purification or isolation of the biomolecule according to the method of the invention.Type: GrantFiled: November 8, 2010Date of Patent: April 14, 2015Inventor: Timo Hillebrand
-
Publication number: 20150093804Abstract: A recombinant baculovirus is provided for preparing picornavirus virus-like particles (VLP), wherein Chitinase A (ChiA) and Cathepsin V (v-cath) genes of the recombinant baculovirus are functionally disrupted and the recombinant baculovirus includes a picornavirus capsid protein gene under control of a strong promoter, and includes a protease gene configured for encoding a protease for hydrolyzing the capsid protein under control of a weak promoter. The recombinant baculovirus of the present invention may adopt High Five or Sf-9 cells for manufacturing enterovirus virus-like particles with improved stability and higher yields in comparison with the conventional arts. A method for preparing virus like particles is also herein provided.Type: ApplicationFiled: December 9, 2014Publication date: April 2, 2015Inventors: YU-CHEN HU, SHIH-YEH LIN
-
Patent number: 8993229Abstract: A method for extracting and distinguishing infectious norovirus from inactive norovirus using a solid support conjugated with a glycoprotein moiety capable of binding infectious norovirus wherein the presence of infectious norovirus is determined using RT-PCR after elution of the infectious norovirus from the solid support.Type: GrantFiled: August 29, 2012Date of Patent: March 31, 2015Assignee: The United States of America, as represented by the Secretary of AgricultureInventor: David H. Kingsley
-
Publication number: 20150064770Abstract: Various aspects and embodiments of the invention are directed to high-throughput phage-engineering methods and recombinant bacteriophages with tunable host ranges for controlling phage specificity.Type: ApplicationFiled: September 5, 2014Publication date: March 5, 2015Applicant: Massachusetts Institute of TechnologyInventors: Timothy Kuan-Ta Lu, Hiroki Ando, Sebastien Lemire
-
Patent number: 8969011Abstract: A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration device comprising a sintered porous polymer matrix comprising at least one concentration agent that comprises an amorphous metal silicate and that has a surface composition having a metal atom to silicon atom ratio of less than or equal to 0.5, as determined by X-ray photoelectron spectroscopy (XPS); (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration device with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration device.Type: GrantFiled: March 22, 2010Date of Patent: March 3, 2015Assignee: 3M Innovative Properties CompanyInventors: Manjiri T. Kshirsagar, Andrew W. Rabins
-
Patent number: 8956812Abstract: A novel process for the purification of recombinant protein expressed as particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals.Type: GrantFiled: August 23, 2004Date of Patent: February 17, 2015Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Srinivas Kannappa Vellimedu
-
Publication number: 20150037874Abstract: The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.Type: ApplicationFiled: August 20, 2014Publication date: February 5, 2015Inventors: Paul HARDEN, Terry HERMISTON, Irene KUHN
-
Publication number: 20150037284Abstract: The present invention relates to a novel Listeria bacteriophage designated ProCC P825. In particular, the present invention relates to the endolysin PlyP825 encoded by the novel phage ProCC P825 and uses of the novel endolysin PlyP825 for controlling Listeria contamination and infection.Type: ApplicationFiled: May 29, 2012Publication date: February 5, 2015Applicant: DSM IP ASSETS B.V.Inventors: Holger Grallert, Julia Lorenz, Anna Scherzinger
-
Publication number: 20150037873Abstract: The present invention relates to a method for endotoxin removal from a sample comprising the following steps: combining the sample comprising one or more target molecule(s) with a chromatography media comprising beads having an inner porous core functionalized with ligands capable of binding endotoxin and an outer porous layer without functional groups and a pore size small enough to exclude the target molecule from the inner core; and collecting the sample from the media, wherein the sample comprises an endotoxin level which is at least 75% less, preferably 90% less, than before the removal and the yield of the target molecule is at least 75%.Type: ApplicationFiled: February 27, 2013Publication date: February 5, 2015Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Patrik Adielsson, Tobias E. Soderman, Anna Akerblom
-
Patent number: 8945584Abstract: A robust and genetically stable cell culture system for Hepatitis C Virus (HCV) genotype 3a is provided. A genotype 3a/2a (S52/JFH1) recombinant containing the structural genes (Core, E1, E2), p7 and NS2 of strain S52 was constructed and characterized in Huh7.5 cells. S52/JFH1 and J6/JFH viruses passaged in cell culture had comparable growth kinetics and yielded similar peak HCV RNA titers and infectivity titers. Direct genome sequencing of cell culture derived S52/JFH1 viruses identified putative adaptive mutations in Core, E2, p7, NS3, and NS5A; clonal analysis revealed that all genomes analyzed exhibited different combinations of these mutations. Finally, viruses resulting from transfection with RNA transcripts of five S52/JFH1 recombinants containing these combinations of putative adaptive mutations performed as efficiently as J6/JFH viruses in Huh7.5 cells and were all genetically stable after viral passage.Type: GrantFiled: April 11, 2008Date of Patent: February 3, 2015Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Troels Kasper Høyer Scheel, Jesper Eugen-Olsen, Jens Bukh
-
Patent number: 8945904Abstract: Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.Type: GrantFiled: May 20, 2011Date of Patent: February 3, 2015Assignee: Novartis AGInventors: Heidi Trusheim, Peter Mason, Michael Franti, Bjoern Keiner, Melissa Sackal, Juerg Hunziker, Francois Natt, David Morrissey
-
Patent number: 8945581Abstract: The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.Type: GrantFiled: October 24, 2011Date of Patent: February 3, 2015Assignee: Transgene S.A.Inventors: Daniel Malarme, Yves Cordier, Claude Sene
-
Publication number: 20150030565Abstract: The present invention provides a method to prepare purified enveloped (e.g., flavivirus) viral particle preparations employing ion exchange chromatography and tangential flow filtration.Type: ApplicationFiled: January 8, 2013Publication date: January 29, 2015Applicant: Sanofi Pasteur Biologics, LLCInventors: Sophia Mundle, Stephen Anderson
-
Patent number: 8940517Abstract: The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards. More specifically, the disclosure provides fast and robust methods of separating antigens from vaccine compositions, comprising the steps of solubilizing antigen without detergent and without alkylation, using acidification to prevent antigen subtypes from binding again, isolating antigen subtypes with chromatography, and quantifying the eluted antigen with amino acid analysis. The methods of the disclosure are applicable for use with a variety of antigens, thereby providing an improved method in the art of vaccine manufacturing to date.Type: GrantFiled: April 18, 2012Date of Patent: January 27, 2015Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Michael Graninger, Martin Kaliwoda
-
Publication number: 20150024467Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.Type: ApplicationFiled: December 16, 2011Publication date: January 22, 2015Applicant: GENZYME CORPORATIONInventors: Pauline McLean Quigley Sheldon, Peter S. Gagnon, Gina Nichols, Barbara A. Thorne
-
Publication number: 20150017205Abstract: The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.Type: ApplicationFiled: July 15, 2014Publication date: January 15, 2015Inventors: Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping
-
Patent number: 8932607Abstract: Described is a composition comprising a plurality of recombinant adenovirus particles, being a recombinant human adenovirus of serotype 5, 26, 34, 35, 48, 49 or 50, or a recombinant simian adenovirus, characterized in that the genomes of essentially all adenovirus particles in the composition comprise as the 5? terminal nucleotides the nucleotide sequence: CTATCTAT (nucleotides 1-8 of SEQ ID NO:7). Also described are methods to produce such compositions.Type: GrantFiled: March 11, 2013Date of Patent: January 13, 2015Assignee: Crucell Holland B.V.Inventors: Jerome H. H. V. Custers, Jort Vellinga
-
Patent number: 8932580Abstract: The present invention relates to a method for the selective purification of bacterial cells and/or cell components, whereby the purification is performed by means of a solid support.Type: GrantFiled: July 28, 2009Date of Patent: January 13, 2015Assignees: Hyglos Invest GmbH, Biomerieux S.A.Inventors: Michael Schutz, Renate Grassl, Roman Meyer, Sibylle Frick, Ingrid Robl, Thomas Zander, Stefan Miller
-
Publication number: 20150010593Abstract: The present invention provides genetically modified cells useful for viral replication and the production of viral vaccines.Type: ApplicationFiled: January 10, 2013Publication date: January 8, 2015Inventors: Marciela Degrace, Nir Hacohen, Sagi Shapira, Liguo Wu
-
Publication number: 20150010983Abstract: Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.Type: ApplicationFiled: September 19, 2014Publication date: January 8, 2015Inventors: Dan T. Stinchcomb, Jill A. Livengood, O'Neil Wiggan, Richard Kinney, Jorge Osorio
-
Publication number: 20150004195Abstract: The present disclosure provides a method to prepare purified enveloped viral particle preparations employing ion ex change chromatography and tangential flow filtration.Type: ApplicationFiled: January 9, 2013Publication date: January 1, 2015Inventors: Sophia Mundle, Stephen Anderson, Simon Delagrave
-
Patent number: 8911744Abstract: The invention relates to a recombinant classical swine fever virus (CSFV). A preferred recombinant CSFV comprises a deletion of at least one amino acid in a “TAVSPTTLR” domain of the E2 protein. The invention further relates to a vaccine comprising the recombinant CSFV, a method for generating a recombinant CSFV, and use of a recombinant CSFV.Type: GrantFiled: December 23, 2009Date of Patent: December 16, 2014Assignee: Intervet International B.V.Inventors: Jeroen Alexander Kortekaas, Rianka Petronella Maria Vloet
-
Patent number: 8911975Abstract: The present invention discloses a cell system, as a host cell to be infected with an F gene-deficient virus, which can constitutively and stably express the F protein, and a method for producing an F gene-deficient virus by utilizing the cell. A non-proliferative human parainfluenza type 2 virus vector is produced by co-culturing an F gene-deficient human parainfluenza type 2 virus with a Vero cell having the F gene of human parainfluenza type 2 virus in such a manner that the F gene is non-inducibly expressed, and isolating viral particles from a culture supernatant.Type: GrantFiled: February 8, 2012Date of Patent: December 16, 2014Assignees: Mie University, BioComo Inc.Inventors: Masayuki Fukumura, Mitsuo Kawano, Tetsuya Nosaka, Junpei Ohtsuka
-
Publication number: 20140363808Abstract: Provided is aptamers screening method based on graphene without target immobilization and the aptamers obtained from the method, and more particularly, a new GO-SELEX method without target immobilization in which a single-stranded nucleic acid pool may react with a non-bound target material or a counter-target material, after which a single-stranded nucleic acid which has not been bound to the target or counter-target may be separated by using the graphene. Also, the specific aptamer obtained through the above-described method may be used for diagnosing target related diseases.Type: ApplicationFiled: August 30, 2012Publication date: December 11, 2014Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventors: Man Bock Gu, Jee Woong Park, Tatavarty Rameshwar
-
Publication number: 20140342918Abstract: The disclosure relates to a switchable aptamer having a high affinity for a selected target such as a virus, cell or antibody when in the presence of a binding ion and a low affinity for said target in the absence of said binding ion. The switchable aptamer may be isolated from a pool comprising a mixture of aptamers by incubating the pool with the target ligand and a binding ion to form target-aptamer complexes; separating unbound aptamer molecules from the target-aptamer complexes; contacting the target-aptamer complexes with a chelating agent having affinity for the binding ion wherein a switchable aptamer specific to said target is released from the target-aptamer complexes; and isolating the switchable aptamer released in the preceding step.Type: ApplicationFiled: May 14, 2014Publication date: November 20, 2014Applicant: UNIVERSITY OF OTTAWAInventors: Maxim V. Berezovski, Mohamed Wehbe, Mahmoud Aziz Mahmoud Labib, Darija Muharemagic, Anna S. Zamay, Shahrokh Ghobadloo
-
Publication number: 20140342434Abstract: The present invention relates to a separation of viruses of an essentially spherical shape from viruses with a rod-like shape that are comprised in a sample, wherein the sample comprising the viruses is subjected to filtration.Type: ApplicationFiled: September 9, 2012Publication date: November 20, 2014Applicant: UNIQURE IP B.V.Inventors: Wilhelmus Theodorus Johannes Maria Christiaan Hermens, James Patrick Smith
-
Publication number: 20140335566Abstract: Embodiments described herein relate to mobile biologics production systems that can be transported to a site where a production of biologics is required, and is operable to produce the biologics on-site on demand. A mobile biologics production system can include a mobile carrier configured to be trailered to a biologics production location. The mobile carrier defines an interior volume configured to provide an aseptic environment for manufacturing, production, and purification of biologics. A production sub-system disposed in the interior volume includes a single-use bioreactor configured to grow biologics which can include microbes, mammalian cell lines, insect cell lines, and plant cell lines. The bioreactor is controlled by a controller, and can have a working capacity of less than about 100 L. A purification sub-system disposed in the internal volume is fluidically coupled to the production sub-system and configured to produce a finished biologic product.Type: ApplicationFiled: September 5, 2013Publication date: November 13, 2014Applicant: BioCapacity On Demand, LLCInventors: Michael Nicholas Guerini, Robert O. Keene
-
Patent number: 8883481Abstract: A method for rescuing a virus by reverse genetics is provided in which cells are added after transfection.Type: GrantFiled: October 20, 2010Date of Patent: November 11, 2014Assignee: Novartis AGInventors: Philip Dormitzer, Björn Keiner, Pirada Suphaphiphat, Michael Franti, Peter Mason, Jennifer Uhlendorff, Mikhail Matrosovich
-
Patent number: 8877210Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: January 15, 2014Date of Patent: November 4, 2014Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 8877448Abstract: The invention provides a composition useful to prepare influenza A viruses, e.g., in the absence of helper virus.Type: GrantFiled: May 12, 2011Date of Patent: November 4, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann
-
Patent number: 8877209Abstract: The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.Type: GrantFiled: May 23, 2011Date of Patent: November 4, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann
-
Publication number: 20140322265Abstract: The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.Type: ApplicationFiled: November 30, 2012Publication date: October 30, 2014Inventors: Paul Chaplin, Robin Steigerwald
-
Patent number: 8859231Abstract: Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a different influenza subtype are also described, as are VLPs in which a portion or all of HA or NA is replaced by a heterologous moiety not produced by influenza virus, so as to comprise chimeric VLPs.Type: GrantFiled: June 2, 2009Date of Patent: October 14, 2014Assignee: Wyeth LLCInventors: Jose M. Galarza, Theresa E. Latham
-
Patent number: 8859208Abstract: The invention provides compositions and methods useful to prepare segmented, negative strand RNA viruses, e.g., orthomyxoviruses such as influenza A viruses, entirely from cloned cDNAs and in the absence of helper virus.Type: GrantFiled: April 20, 2005Date of Patent: October 14, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann
-
Patent number: 8852915Abstract: A method of retrovirus storage, characterized in that a retrovirus is sustained in the presence of a substance with retrovirus binding activity immobilized on a solid phase. Further, there is provided a retrovirus composition characterized in that a retrovirus in the form of binding to a substance with retrovirus binding activity is sealed in a container holding a solid phase having the substance with retrovirus binding activity immobilized thereon.Type: GrantFiled: October 12, 2012Date of Patent: October 7, 2014Assignee: Takara Bio Inc.Inventors: Hideto Chono, Yasushi Katayama, Hiromi Okuyama, Junichi Mineno, Kiyozo Asada, Ikunoshin Kato
-
Patent number: 8846368Abstract: Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more Salmonella bacteria selected from the group consisting of Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum, and Salmonella pullorum without affecting beneficial bacteria, in addition to showing excellent tolerance to acid, heat and desiccation. The novel bacteriophage of the present invention can be widely used as an active ingredient for therapeutic agents, animal feeds or drinking water, cleaners and sanitizers for preventing and treating the infectious diseases caused by Salmonella enteritidis, Salmonella typhimurium, Salmonella gallinarum or Salmonella pullorum including salmonellosis, Salmonella food poisoning, Fowl Typhoid, and Pullorum disease or for controlling the Salmonella bacteria.Type: GrantFiled: September 17, 2012Date of Patent: September 30, 2014Assignee: CJ Cheiljedang CorporationInventors: Soo An Shin, Min Tae Park, Hyang Choi, Young Wook Cho, In Hye Kang, Su Jin Choi
-
Publication number: 20140273159Abstract: A process for remediation of target bacteria, particularly sulfur reducing bacteria (SRB), in waters (“target water”) having a multiplicity and diverse host target bacteria by employing serial or staged bacteria culturing and lysing of dominant bacteria. Remediation of sulfur reducing bacteria (SRB) is effected by application of a series of bacteriophage isolated from the staged culturing and bacteriophage lysing of successive aliquots of waters containing a multiplicity of SRB.Type: ApplicationFiled: October 17, 2013Publication date: September 18, 2014Inventors: Elizabeth J. Summer, Mei Liu, Neil S. Summer, Douglas Baldwin
-
Patent number: 8828407Abstract: The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein.Type: GrantFiled: July 5, 2010Date of Patent: September 9, 2014Assignee: The Pirbright InstituteInventors: Paul Britton, Erica Bickerton, Maria Armesto
-
Patent number: 8828406Abstract: Described herein are chimeric influenza virus gene segments and nucleic acid sequences encoding such chimeric influenza virus gene segments. A chimeric influenza virus gene segment described herein comprises packaging signals found in the non-coding and coding regions of one type of influenza virus gene segment and an open reading frame of a different type of influenza virus gene segment or fragment thereof. Also described herein are recombinant influenza viruses comprising two or more chimeric influenza virus gene segments and the use of such viruses in the prevention and/or treatment of influenza virus disease.Type: GrantFiled: July 29, 2010Date of Patent: September 9, 2014Assignee: Icahn School of Medicine at Mount SinaiInventors: Adolfo Garcia-Sastre, Peter Palese, Qinshan Gao
-
Publication number: 20140242671Abstract: This invention relates to a HEK293 cell line that grows under animal component-free suspension conditions. The cell line is ideal for rapid and scalable production of adeno-associated virus (AAV) and supports production of all serotypes and chimera of AAV.Type: ApplicationFiled: October 26, 2012Publication date: August 28, 2014Inventors: Joshua Grieger, Richard Jude Samulski
-
Patent number: 8815252Abstract: The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.Type: GrantFiled: November 25, 2009Date of Patent: August 26, 2014Assignee: Baxter Healthcare SAInventors: Julia Romanova, Andrej Egorov, Brigitte Krenn, Markus Wolschek, Sabine Nakowitsch
-
Publication number: 20140227766Abstract: Materials and methods for use of constrained cohydration agents in the purification of biological materials such as antibodies, viruses, cells, and cellular organelles in connection with convective chromatography, fluidized bed or co-precipitation applications.Type: ApplicationFiled: June 1, 2012Publication date: August 14, 2014Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventor: Peter Stanley Gagnon
-
Patent number: 8802417Abstract: The present invention discloses methods for producing and/or propagating virus particles, such as influenza virus particles, that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle. The invention also provides a method for selective propagation of a set of virus particles, such as influenza virus particles present in an influenza isolate, which have an affinity for receptors comprising a specific glycosylation residue.Type: GrantFiled: July 16, 2007Date of Patent: August 12, 2014Assignee: Crucell Holland B.V.Inventors: Giuseppe Marzio, Maria Grazia Pau, Dirk Jan Elbertus Opstelten, Alphonsus Gerardus Cornelis Maria Uytdehaag
-
Patent number: 8795681Abstract: The present invention relates to recombinant raccoon poxvirus vectors that express the rabies virus glycoprotein gene at the hemagglutinin (ha) locus of the poxvirus genome or express the glycoprotein gene of the same or different rabies strains at the thymidine kinase (tk) and the hemagglutinin (ha) loci of the poxvirus genome, and their use as adjuvant-free vaccines. The raccoon poxvirus vector comprises the nucleic acid molecules encoding the glycoprotein of a Challenge Virus Standard rabies strain inserted and expressed at the tk locus of the poxvirus genome and of a Pasteur-Paris rabies strain inserted and expressed at the ha locus of the poxvirus genome. The vaccine may optionally contain a mixture of additional feline and canine antigens for immunization of animals. Also disclosed are methods for inducing an immune response to rabies in a mammal by administering to the mammal an effective immunizing amount of the vaccine of the invention.Type: GrantFiled: May 28, 2008Date of Patent: August 5, 2014Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Stephen Qitu Wu, Michael A. Gill, Hsien-Jue Chu
-
Patent number: 8795999Abstract: This invention relates to adsorbents and methods for highly selective removal of anti-von Willebrand Factor-cleaving protease antibodies (“anti-vWF-cp-abs”) from human plasma using human von Willebrand Factor-cleaving protease (“hvWF-cp”) or fragments thereof as affinity ligands. The adsorbents can be used for treating disorders associated with the occurrence of anti-vWF-cp-abs in patients, such as thromboembolic diseases.Type: GrantFiled: February 18, 2009Date of Patent: August 5, 2014Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Friedrich Scheiflinger, Barbara Plaimauer, Gerhard Antoine
-
Publication number: 20140205629Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: March 28, 2014Publication date: July 24, 2014Applicant: AlphaVax, Inc.Inventors: Jon O. RAYNER, Jonathan F. SMITH, Bolyn HUBBY, Elizabeth A. REAP
-
Publication number: 20140206062Abstract: The invention provides compositions and methods useful to prepare segmented, negative strand RNA viruses, e.g., orthomyxoviruses such as influenza A viruses, entirely from cloned cDNAs and in the absence of helper virus.Type: ApplicationFiled: January 17, 2014Publication date: July 24, 2014Applicant: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann
-
Publication number: 20140205628Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.Type: ApplicationFiled: December 16, 2013Publication date: July 24, 2014Applicant: WORLD FORCE TECHNOLOGIES, LLCInventors: Thomas W. Konowalchuk, Jack Konowalchuk